1Brandao CM, Machado GP, Acurcio FD.Pharmacoeconomic analysis of strategies to treat posUnenopausal osteoporosis: a systematic review[J]. Rev Bras Reumatol, 2012, 52(6): 924-937.
2Hampson G, Fogelman l.Clinical role of bisphosphonate therapy[J]. Int J Womens Health, 2012, 4: 455-469.
3Napoli N, Armamento-Villareal R.Estrogen hydroxylation in osteoporosis[J]. Adv Clin Chem, 2007, 43:2 l 1-227.
4Seelig MS, Altura BM, Altura BT.Benefits and risks of sex hormone replacement in postrnenopausal women[J]. J Am Coll Nun', 2004, 23(5): 482S-496S.
5Richette P, Roux C. Impact of treatments for osteoporosis on cartilage biomarkers in humans[J]. Osteoporos Int, 2012, 23, 8: 877-880.
6Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fiactures in men and women with low bone density or osteoporosis: update of the 2007 report[J]. J Manag Care Pharm, 2012, 18(4 Suppl B): SI-S15.
7Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with posUrlenopausal osteoporosis[J]. CalcifTissue Int, 2011, 89(2): 91-104.
8Lin T, Wang C, Cai XZ, et al.Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis[J]. Int J Clin Pmct, 2012, 66(4): 399-408.
9Baron R, Hesse E. Update on bone anabolics in osteopomsis treatment: rationale, cun'ent status, and perspectives]J]. J Clin Endoerinol Metab, 2012,107(2): 311-325.
10Horwitz ML Tedesco MB, Garcia-Ocana A, et al. Parathyroid hormone-related protein for tile treatment of postmenopausal ostenporosis: defining the maximal tolerable dose[J]. J Clin Endocrinol Metab, 2010, 105(3): 12710-12787.
